Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: SELL (auto-tracking)
2.45% $40.91
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 307.48 mill |
EPS: | 1.290 |
P/E: | 31.71 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 31.96 mill |
Avg Daily Volume: | 0.451 mill |
RATING 2024-03-27 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 31.71 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.66x |
Company: PE 31.71 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.0456 (-99.89%) $-40.86 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 39.73 - 42.09 ( +/- 2.89%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Smith Thomas B | Sell | 995 | Common Stock |
2024-02-26 | Dreyer Scott | Sell | 9 336 | Common Stock |
2024-02-26 | Dreyer Scott | Sell | 664 | Common Stock |
2024-02-12 | Tupper Colleen | Buy | 30 856 | Common Stock |
2024-02-12 | Tupper Colleen | Sell | 16 868 | Common Stock |
INSIDER POWER |
---|
14.73 |
Last 100 transactions |
Buy: 1 331 449 | Sell: 1 023 987 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $40.91 (2.45% ) |
Volume | 0.350 mill |
Avg. Vol. | 0.451 mill |
% of Avg. Vol | 77.63 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $33.13 | N/A | Active |
---|
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.